Exelixis Announces Webcasts of Investor Conference Presentations in March
March 05 2019 - 4:05PM
Business Wire
� Presentations to be webcast on
www.exelixis.com �
Exelixis, Inc. (NASDAQ: EXEL) today announced that the
company will be presenting at the following investor conferences in
March:
- Cowen & Co. 39th Annual Health Care
Conference: Exelixis is scheduled to present at 8:00
AM EDT / 5:00 AM PDT on Tuesday, March 12,
2019 in Boston.
- Barclays Global Healthcare Conference
2019: Exelixis is scheduled to present at 9:30 AM
EDT / 6:30 AM PDT on Wednesday, March 13,
2019 in Miami Beach.
- Oppenheimer & Co. 29th Annual
Healthcare Conference: Exelixis is scheduled to present at 10:20 AM
EDT / 7:20 AM PDT on Tuesday, March 19, 2019 in New York.
To access the webcast links, log
onto www.exelixis.com and proceed to the News &
Events / Event Calendar page under the Investors & Media
heading. Please connect to the company’s website at least 15
minutes prior to each presentation to ensure adequate time for any
software download that may be required to listen to the webcasts.
Replays will also be available at the same location for 14 days
following each presentation.
About Exelixis
Founded in 1994, Exelixis, Inc. (Nasdaq: EXEL) is a commercially
successful, oncology-focused biotechnology company that strives to
accelerate the discovery, development and commercialization of new
medicines for difficult-to-treat cancers. Following early work in
model genetic systems, we established a broad drug discovery and
development platform that has served as the foundation for our
continued efforts to bring new cancer therapies to patients in
need. Our discovery efforts have resulted in four approved
products, CABOMETYX® (cabozantinib), COMETRIQ® (cabozantinib),
COTELLIC® (cobimetinib) and MINNEBRO™ (esaxerenone), and we have
entered into partnerships with leading pharmaceutical companies to
bring these important medicines to patients worldwide. Supported by
revenues from our marketed products and collaborations, we are
committed to prudently reinvesting in our business to maximize the
potential of our pipeline. We are supplementing our existing
therapeutic assets with targeted business development activities
and internal drug discovery — all to deliver the next generation of
Exelixis medicines and help patients recover stronger and live
longer. Exelixis is a member of the Standard & Poor’s (S&P)
MidCap 400 index, which measures the performance of profitable
mid-sized companies. For more information about Exelixis, please
visit http://www.exelixis.com, follow @ExelixisInc on Twitter or
like Exelixis, Inc. on Facebook.
Exelixis, the Exelixis logo, CABOMETYX,
COMETRIQ and COTELLIC are registered U.S. trademarks.
MINNEBRO is a Japanese trademark.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190305005932/en/
Investors Contact:Susan HubbardEVP, Public Affairs and
Investor RelationsExelixis,
Inc.650-837-8194shubbard@exelixis.com
Media Contact:Hal MackinsFor Exelixis,
Inc.415-994-0040hal@torchcommunications.com
Exelixis (NASDAQ:EXEL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Exelixis (NASDAQ:EXEL)
Historical Stock Chart
From Apr 2023 to Apr 2024